grant
Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancer
Organization FRED HUTCHINSON CANCER CENTERLocation SEATTLE, UNITED STATESPosted 1 Apr 2021Deadline 31 Mar 2028
NIHUS FederalResearch GrantFY2026AIK geneARK1AURKAAURORA2Aik proteinAntimitotic AgentsAntimitotic DrugsAntimitoticsAurora-Related Kinase 1Aurora/IPL1-Like KinaseB-raf-1BRAFBRAF geneBTAKBiochemicalBiologicalC-K-RASCRISPR editing screenCRISPR screenCRISPR-based screenCRISPR/Cas9 screenCancer GenesCancer TreatmentCancer cell lineCancer-Promoting GeneCancersCell BodyCell Communication and SignalingCell SignalingCellsCellular TransformationChromosomal RearrangementClinical TrialsComplexCoupledDNA mutationDataDevelopmentDiseaseDisorderDrug ScreeningDrug resistanceEGF ReceptorEGFRERBB ProteinEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor KinaseEpidermal Growth Factor Receptor Protein-Tyrosine KinaseEpidermal Growth Factor-Urogastrone ReceptorsEpithelial CellsEventFDA approvedFamilyGEM modelGEMM modelGenesGeneticGenetic ChangeGenetic defectGenetic mutationGenetically Engineered MouseGenomicsGenotypeGerm LinesGoalsGranulocytic LeukemiaHER1HumanImpairmentIndividualIntracellular Communication and SignalingK-RAS2AK-RAS2BK-RasK-Ras 2AK-Ras-2 OncogeneKRASKRAS2KRAS2 geneKi-RASLaboratoriesLungLung AdenocarcinomaLung NeoplasmsLung Respiratory SystemLung TumorMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMalignant Tumor of the LungMalignant neoplasm of lungMapsMediatingMicrotubular Function InhibitorsMitosis CheckpointMitosis Inhibitor AgentsMitosis Inhibitor DrugsMitosis InhibitorsMitotic CheckpointMitotic Inhibitor AgentsMitotic Inhibitor DrugsMitotic InhibitorsModern ManMolecularMonomeric G-ProteinsMonomeric GTP-Binding ProteinsMutateMutationMyelocytic LeukemiaMyelogenous LeukemiaMyeloid LeukemiaNatureNon-Lymphoblastic LeukemiaNon-Lymphocytic LeukemiaNonlymphoblastic LeukemiaNonlymphocytic LeukemiaNoonan SyndromeOncogene K-RasOncogenesOncogenesisOncogenicPDX modelPTK ReceptorsPathogenicityPathway interactionsPatient derived xenograftPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPatternPlayPostdocPostdoctoral FellowPrecision therapeuticsPreclinical dataProteinsProteomicsPulmonary CancerPulmonary NeoplasmsPulmonary malignant NeoplasmRAFB1RASK2Receptor Protein-Tyrosine KinasesReceptor Tyrosine Kinase GeneRegulationResearch AssociateResistanceRoleSTK15STK6STK6 geneSTK6, Mouse, Homolog ofSerine/Threonine Protein Kinase 15Signal TransductionSignal Transduction SystemsSignalingSmall G-ProteinsSmall GTPasesStructureSurvival RateTCGATGF-alpha ReceptorTestingThe Cancer Genome AtlasTherapeuticTransforming GenesTransforming Growth Factor alpha ReceptorTranslatingTranslationsTransmembrane Receptor Protein Tyrosine KinaseTurner phenotype with normal karyotypeTurner syndrome in female with X chromosomeTurner-like syndromeTyrosine Kinase Linked ReceptorsTyrosine Kinase ReceptorsUllrich-Noonan syndromeUnited StatesUrogastrone ReceptorVariantVariationWorkanti-cancer therapyaurora kinasaurora kinaseaurora kinase Aaurora-kinase Abiologicbiological signal transductionc-erbB-1c-erbB-1 Proteincancer sub-typescancer subtypescancer therapycancer-directed therapyclinical practiceclustered regularly interspaced short palindromic repeats screendevelopmentaldriver lesiondriver mutationdrug resistantefficacy testingerbB-1erbB-1 Proto-Oncogene ProteinerbBlexperimentexperimental researchexperimental studyexperimentsfamilial Turner syndromefunctional genomicsgain of function mutationgenetically engineered mouse modelgenetically engineered murine modelgenome mutationgenome scalegenome-widegenomewideimprovedimproved outcomeindividualized cancer careindividualized oncologyinhibitorinsightkinase inhibitorlung cancerlung cancer celllung tumorigenesismale Turner syndromemalignancymetaplastic cell transformationmitosis check pointmitotic check pointmutantmyeloid granulocytic leukemiamyelosisneoplasm/cancernew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapeuticsnew therapynew therapy approachesnew treatment approachnew treatment strategynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapeuticsnovel therapynovel therapy approachoverexpressoverexpressionparent grantpathwaypatient derived xenograft modelpatient oriented outcomespersonalized oncologypost-docpost-doctoralpost-doctoral traineepre-clinical studyprecision cancer careprecision cancer medicineprecision oncologyprecision therapiesprecision treatmentpreclinical findingspreclinical informationpreclinical studyprotein complexproto-oncogene protein c-erbB-1pseudo-Ullrich-Turner syndromeras Gene Productsras Proteinsresearch associatesresistance to Drugresistantresistant to Drugsmall moleculesocial rolesynergismtargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttranslationtranslational opportunitiestranslational potentialtreatment strategytumortumorigenesistumorigenesis in the lungtumorigenicv-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homologv-raf Murine Sarcoma Viral Oncogene Homolog B1
Description preview
PROJECT SUMMARY/ABSTRACT (of parent grant)
Recent advances in targeted therapies have revolutionized lung cancer clinical practice. Lung adenocarcinomas
harbor frequent mutations/amplifications/fusions in receptor tyrosine kinase (RTK) and RAS pathway
oncogenes, many of which can be targeted by FDA-approved therapies. However, the majority of…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click